Molecular biologic substaging of stage I lung cancer according to gender and histology

D’Amico, Thomas A.; Aloia, Thomas A.; Moore, Mary B.; Herndon, James E.; Brooks, Kelli; Lau, Christine L.; Harpole, David H.

doi:10.1016/s0003-4975(99)01522-2

Cited by 78 publications

(33 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemistry used to reveal Ki-67 protein was not always performed with the same antibody: clone Mib-1 in the majority of the studies (Costes et al, 1995;Bohm et al, 1996;Fontanini et al, 1996;Bellotti et al, 1997;Ishida et al, 1997;Komaki et al, 1998;Dazzi et al, 1999;Dingemans et al, 1999Dingemans et al, , 2001Santinelli et al, 1999;Cagini et al, 2000;Demarchi et al, 2000;Hommura et al, 2000;Nguyen et al, 2000;Shiba et al, 2000Shiba et al, , 2001van de Vaart et al, 2000;Ferreira et al, 2001;Hayashi et al, 2001;Puglisi et al, 2001Puglisi et al, , 2002Ramnath et al, 2001;Tsoli et al, 2001;Minami et al, 2002;Rigau et al, 2002), antibodies coming from a firm selling several clones but without mention of the clone used (Hayashi et al, 1993;Pence et al, 1993;Kawai et al, 1994;Giaccone et al, 1995;Pujol et al, 1996;Mehdi et al, 1998;Soomro et al, 1998;Carbognani et al, 2002); any mention of the antibodies used (Tungekar et al, 1991;Harpole Jr et al, 1995Giatromanolaki et al, 1996a, b;D'Amico et al, 1999D'Amico et al, , 2000Carvalho et al, 2000;Pelosi et al, 2001)…”

Section: Discussionmentioning

confidence: 99%

“…The antibodies concentration is also a factor having an influence on the staining result because of the intensity is correlated to the antibody concentration used. This aspect of the immunohistochemistry does not seem important for some authors because they do not specify the antibodies concentration (Tungekar et al, 1991;Hayashi et al, 1993;Costes et al, 1995;Harpole Jr et al, 1995Giatromanolaki et al, 1996a, b;Pujol et al, 1996;D'Amico et al, 1999D'Amico et al, , 2000Dazzi et al, 1999;Santinelli et al, 1999;Nguyen et al, 2000;Shiba et al, 2000Shiba et al, , 2001Pelosi et al, 2001;Carbognani et al, 2002;Minami et al, 2002). Sometimes the immunohistochemical technique was performed without prior reaction for unmasked epitope on fixed tissue.…”

Section: Discussionmentioning

confidence: 99%

“…In total, 42 studies published between 1991 and 2002 were selected for this systematic review (Tungekar et al, 1991;Hayashi et al, 1993;Pence et al, 1993;Kawai et al, 1994;Costes et al, 1995;Giaccone et al, 1995;Harpole, Jr et al, 1995Bohm et al, 1996;Fontanini et al, 1996;Giatromanolaki et al, 1996a, b;Pujol et al, 1996;Bellotti et al, 1997;Ishida et al, 1997;Komaki et al, 1998;Mehdi et al, 1998;Soomro et al, 1998;D'Amico et al, 1999D'Amico et al, , 2000Dazzi et al, 1999;Dingemans et al, 1999Dingemans et al, , 2001Santinelli et al, 1999;Cagini et al, 2000;Carvalho et al, 2000;Demarchi et al, 2000;Hommura et al, 2000;Nguyen et al, 2000;Shiba et al, 2000Shiba et al, , 2001van de Vaart et al, 2000;Ferreira et al, 2001;Hayashi et al, 2001;Pelosi et al, 2001;Puglisi et al, 2001Puglisi et al, , 2002Ramnath et al, 2001;Tsoli et al, 2001;Carbognani et al, 2002;Minami et al, 2002;Rigau et al, 2002). Five were excluded because an identical patients cohort was used in another selected publication (references excluded/includ...…”

Section: Studies Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

et al. 2004

View full text Add to dashboard Cite

Among new biological markers that could become useful prognostic factors for lung carcinoma, Ki-67 is a nuclear protein involved in cell proliferation regulation. Some studies have suggested an association between Ki-67 and poor survival in lung cancer patients. In order to clarify this point, we have performed a systematic review of the literature, using the methodology already described by our Group, the European Lung Cancer Working Party. In total, 37 studies, including 3983 patients, were found to be eligible. In total, 49% of the patients were considered as having a tumour positive for the expression of Ki-67 according to the authors cutoff. In all, 29 of the studies dealt with non-small-cell lung carcinoma (NSCLC), one with small-cell carcinoma (SCLC), two with carcinoid tumours and five with any histology. In terms of survival results, Ki-67 was a bad prognosis factor for survival in 15 studies while it was not in 22. As there was no statistical difference in quality scores between the significant and nonsignificant studies evaluable for the meta-analysis, we were allowed to aggregate the survival results. The combined hazard ratio for NSCLC, calculated using a random-effects model was 1.56 (95% CI: 1.30 -1.87), showing a worse survival when Ki-67 expression is increased. In conclusion, our meta-analysis shows that the expression of Ki-67 is a factor of poor prognosis for survival in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Studies Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Seven of the articles Fontanini et al, 1996Fontanini et al, , 1997bFontanini et al, , 1998aHarpole et al, 1996;Takanami et al, 1999;D'Amico et al, 2000) were excluded because identical cohorts of patients were included in other selected publications.…”

Section: Studies Selection and Characteristicsmentioning

confidence: 99%

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

et al. 2002

View full text Add to dashboard Cite

In order to determine whether angiogenesis is a prognostic marker in lung cancer, we performed a systematic review of the literature to assess the prognostic value on survival of microvessel count in patients with lung cancer. Published studies were identified by an electronic search in order to aggregate survival results, after a methodological assessment using a quality scale designed by the European Lung Cancer Working Party. To be eligible, a study had to deal with microvessel count assessment in lung cancer patients on the primary site and to provide survival analysis according to microvessel count expression. Microvessel count has been assessed on surgical samples by immunohistochemistry using factor VIII in 14 studies, CD34 in 10 and CD31 in eight. Respectively 1866, 1440 and 1093 non-small cell lung cancer patients were considered. The overall median quality scores were respectively 52, 59 and 59% for studies assessing microvessel count via factor VIII, CD34 and CD31, without significant difference between studies evaluable or not for meta-analysis nor between studies with significant or non significant results. Seven 'factor VIII' studies, nine 'CD34' and seven 'CD31' provided sufficient data allowing a metaanalysis on survival and were evaluable for results aggregation. This showed that a high microvessel count in the primitive lung tumour was a statistically significant poor prognostic factor for survival in non small cell lung cancer whatever it was assessed by factor VIII (HR: 1.81; 95% CI: 1.16 -2.84), CD34 (HR: 1.99; 95% CI: 1.53 -2.58) or CD31 (HR: 1.80; 95% CI: 1.10 -2.96). Variations in survival among the individual studies can be explained in addition to patients selection criteria by the heterogeneous methodologies used to stain and count microvessels: different antibody clones, identification of 'hotspots', Weidner or Chalkey counting method, cut-off selection. Microvessel count, reflecting the angiogenesis, appears to be a poor prognostic factor for survival in surgically treated non small cell lung cancer but standardisation of angiogenesis assessment by the microvessel count is necessary.

show abstract

“…Indeed, to identify patients with stage I NSCLC who might benefit from adjuvant therapy, investigators have attempted to identify factors predicting poor prognosis. These studies included analysis of performance status, histological subtype, size of the primary tumor, the degree of tumor differentiation, mitotic rate, and evidence of lymphatic or vascular invasion (Feld et al, 1984;D'Amico et al, 1999D'Amico et al, , 2000Suzuki et al, 1999;Liu et al, 2001). However, all of these factors have failed, to date, to precisely identify a group of stage I patients who would benefit from adjuvant therapy.…”

mentioning

confidence: 99%

Role of cell‐cycle regulators in lung cancer

Caputi

Russo

Esposito

et al. 2005

Journal Cellular Physiology

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer death worldwide. Histologically, 80% of lung cancers are classified as non-smallcell lung cancer (NSCLC), and the remaining 20% as small-cell lung cancer (SCLC). Lung carcinoma is the result of molecular changes in the cell, resulting in the deregulation of pathways controlling normal cellular growth, differentiation, and apoptosis. This review summarizes some of the most recent findings about the role of cell-cycle proteins in lung cancer pathogenesis and progression.

show abstract

Molecular biologic substaging of stage I lung cancer according to gender and histology

Cited by 78 publications

References 15 publications

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Role of cell‐cycle regulators in lung cancer

Contact Info

Product

Resources

About